Results 1 to 10 of about 17,851 (159)

The Endothelin Receptor Antagonist Macitentan Inhibits Human Cytomegalovirus Infection [PDF]

Cells, 2021
Human cytomegalovirus (HCMV) infection is an important cause of morbidity and mortality in immunocompromised patients and a major etiological factor for congenital birth defects in newborns.
Natalia Landázuri, Jennifer Gorwood, Ylva Terelius, Fredrik Öberg, Koon Chu Yaiw, Afsar Rahbar, Cecilia Söderberg-Nauclér   +6 more
doaj   +2 more sources

The endothelin receptor antagonist macitentan ameliorates endothelin-mediated vasoconstriction and promotes the survival of retinal ganglion cells in rats [PDF]

Frontiers in Ophthalmology, 2023
Glaucoma is a chronic and progressive eye disease, commonly associated with elevated intraocular pressure (IOP) and characterized by optic nerve degeneration, cupping of the optic disc, and loss of retinal ganglion cells (RGCs).
Bindu Kodati, Bindu Kodati, Wei Zhang, Wei Zhang, Shaoqing He, Jennifer H. Pham, Jennifer H. Pham, Kallen J. Beall, Zoe E. Swanger, Vignesh R. Krishnamoorthy, Payton E. Harris, Trent Hall, Ashley V. Tran, Renuka M. Chaphalkar, Sai H. Chavala, Dorota L. Stankowska, Dorota L. Stankowska, Raghu R. Krishnamoorthy, Raghu R. Krishnamoorthy   +18 more
doaj   +2 more sources

Pipersentan: A De Novo Synthetic Endothelin Receptor Antagonist that Inhibits Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension [PDF]

Frontiers in Pharmacology, 2022
Background: Although major advances have been made in the pathogenesis and management of pulmonary arterial hypertension (PAH), the endothelin system is still considered to play a vital role in the pathology of PAH due to its vasoconstrictive action ...
Zeyu Zhang, Zeyu Zhang, Zeyu Zhang, Chunlei Liu, Chunlei Liu, Yongyi Bai, Xin Li, Xin Li, Xiaojian Gao, Xiaojian Gao, Xiaojian Gao, Chen Li, Chen Li, Ge Guo, Ge Guo, Si Chen, Mingzhuang Sun, Kang Liu, Yang Li, Kunlun He, Kunlun He   +20 more
doaj   +2 more sources

ANTIDIURETIC EFFECTS OF THE ENDOTHELIN RECEPTOR ANTAGONIST AVOSENTAN [PDF]

Frontiers in Physiology, 2012
Several clinical studies have investigated the potential benefits of endothelin receptor antagonism in chronic pathologies such as diabetic kidney disease.
Ovidiu Constantin Baltatu, Ovidiu Constantin Baltatu, Radu eIliescu, Christian eZaugg, Jane F. Reckelhoff, Pat eLouie, Christoph eSchumacher, Luciana Aparecida Campos, Luciana Aparecida Campos   +8 more
doaj   +2 more sources

Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience [PDF]

Therapeutic Advances in Respiratory Disease, 2019
Marion Delcroix
exaly   +2 more sources

A non‐selective endothelin receptor antagonist bosentan modulates kinetics of bone marrow‐derived cells in ameliorating pulmonary hypertension in mice [PDF]

Pulmonary Circulation, 2020
Taichi Kato, Masahiro Masuya, Junkô Maruyama   +2 more
exaly   +2 more sources

Endothelin receptor type A is involved in the development of oxaliplatin-induced mechanical allodynia and cold allodynia acting through spinal and peripheral mechanisms in rats

Molecular Pain, 2021
Oxaliplatin, a platinum-based chemotherapeutic agent, frequently causes severe neuropathic pain typically encompassing cold allodynia and long-lasting mechanical allodynia.
Kae Matsuura, Atsushi Sakai, Yuji Watanabe, Yasunori Mikahara, Atsuhiro Sakamoto, Hidenori Suzuki   +5 more
doaj   +1 more source

Aprocitentan: A new development of resistant hypertension

The Journal of Clinical Hypertension, 2023
As the blood pressure threshold for commencing antihypertensive treatment diminishes, the cohort suffering from resistant hypertension (RH) correspondingly expands.
Yao Yao, Bin Fan, Bin Yang, Zixuan Jia, Bao Li   +4 more
doaj   +1 more source

Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)

Pulmonary Circulation, 2020
Many patients with pulmonary arterial hypertension do not achieve treatment goals with monotherapy, and therefore combination therapy is becoming the standard of care.
Hossein-Ardeschir Ghofrani, Ekkehard Grünig, Pavel Jansa, David Langleben, Stephan Rosenkranz, Ioana R. Preston, Franck Rahaghi, Namita Sood, Dennis Busse, Christian Meier, Marc Humbert   +10 more
doaj   +1 more source

Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors [PDF]

Kidney Research and Clinical Practice, 2022
Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis).
Anthony T. P. Chan, Sydney C. W. Tang
doaj   +1 more source